Pulmonary toxicity of craniospinal irradiation using helical tomotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Joongyo | - |
dc.contributor.author | Kim, Euidam | - |
dc.contributor.author | Kim, Nalee | - |
dc.contributor.author | Suh, Chang-Ok | - |
dc.contributor.author | Chung, Yoonsun | - |
dc.contributor.author | Yoon, Hong In | - |
dc.date.accessioned | 2022-07-06T10:14:08Z | - |
dc.date.available | 2022-07-06T10:14:08Z | - |
dc.date.created | 2022-04-06 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/139485 | - |
dc.description.abstract | Craniospinal irradiation using helical tomotherapy (HT-CSI) has advantages in aspects of homogeneous dose distribution. Physicians, however, still have concerns of pulmonary toxicity due to HT-CSI's relatively large, low-dose irradiated volume from continuous and 360 degrees rotation delivery. In this study, we investigated the pulmonary toxicity of HT-CSI. We retrospectively reviewed 105 patients who received HT-CSI between January 2014 and December 2019. Grade 2 + pulmonary toxicities were evaluated. Intensive systemic treatment was defined as systemic treatment administration before, during, and after HT-CSI. V-X Gy was defined as % volume receiving >= X Gy. Thirteen patients (12.4%) presented with grade 2 + pulmonary toxicities after HT-CSI. Of these patients, only one experienced grade 2 radiation pneumonitis combined with pembrolizumab-induced pneumonitis. Conversely, pneumonia was observed in 12 patients. Intensive systemic treatment (p = 0.004), immunosuppressive drugs (p = 0.031), and bilateral lung V-5 Gy >= 65% (p = 0.031) were identified as independent risk factors for pneumonia. The risk factor for pneumonia in pediatric patients were immunosuppressive drugs (p = 0.035) and bilateral lung V-5 Gy >= 65% (p = 0.047). HT-CSI can be a safe treatment modality with tolerable pulmonary toxicities. Intensive systemic treatment, immunosuppressive drugs, and bilateral lung V-5 Gy >= 65% were significantly associated with pneumonia. In these patients, close follow-up should be considered for proper management of pneumonia. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PORTFOLIO | - |
dc.title | Pulmonary toxicity of craniospinal irradiation using helical tomotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Yoonsun | - |
dc.identifier.doi | 10.1038/s41598-022-07224-1 | - |
dc.identifier.scopusid | 2-s2.0-85125543757 | - |
dc.identifier.wosid | 000761274300013 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.12, no.1, pp.1 - 9 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | PNEUMOCYSTIS-CARINII-PNEUMONIA | - |
dc.subject.keywordPlus | RADIATION PNEUMONITIS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | ELECTRON | - |
dc.subject.keywordPlus | RISK | - |
dc.identifier.url | https://www.nature.com/articles/s41598-022-07224-1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.